AMERIPRISE FINANCIAL INC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 46 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
AMERIPRISE FINANCIAL INC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$31,558,000
+13.4%
35,200,000
+2.9%
0.01%
+11.1%
Q1 2021$27,832,000
+257.5%
34,200,000
+238.6%
0.01%
+200.0%
Q4 2020$7,786,000
-4.1%
10,100,0000.0%0.00%0.0%
Q3 2020$8,120,000
+6.8%
10,100,0000.0%0.00%0.0%
Q2 2020$7,601,000
-5.9%
10,100,0000.0%0.00%
-25.0%
Q1 2020$8,080,000
-66.8%
10,100,000
-58.1%
0.00%
-60.0%
Q4 2019$24,301,000
+10.4%
24,100,000
-5.9%
0.01%0.0%
Q3 2019$22,017,000
+38.7%
25,601,000
+43.8%
0.01%
+42.9%
Q2 2019$15,871,000
-25.1%
17,800,000
-16.8%
0.01%
-30.0%
Q1 2019$21,177,000
-3.8%
21,400,000
-10.5%
0.01%
-9.1%
Q4 2018$22,021,000
-6.1%
23,900,000
+3.0%
0.01%
+37.5%
Q3 2018$23,447,000
+13.0%
23,200,000
-2.1%
0.01%
-11.1%
Q2 2018$20,751,000
+7.0%
23,700,000
-2.1%
0.01%0.0%
Q1 2018$19,390,000
+7.0%
24,200,000
+6.1%
0.01%
+12.5%
Q4 2017$18,125,000
+15.6%
22,800,000
+12.3%
0.01%
+14.3%
Q3 2017$15,681,000
-20.6%
20,300,0000.0%0.01%
-30.0%
Q2 2017$19,741,000
+22.5%
20,300,000
+17.3%
0.01%
+25.0%
Q1 2017$16,121,000
+52.1%
17,300,000
+45.5%
0.01%
+33.3%
Q4 2016$10,596,000
+7.7%
11,890,000
+35.1%
0.01%0.0%
Q3 2016$9,840,0008,800,0000.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2018
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders